BioTuesdays

Category - Markets

Agenus

HCW downgrades Agenus to neutral

H.C. Wainwright downgraded Agenus (NASDAQ:AGEN) to “neutral” from “buy” and slashed its price target to $5 from $10. The stock closed at $4.33 on Thursday. Analyst Swayampakula Ramakanth writes that during Agenus’ third...

CryoLife

Canaccord ups CryoLife price target to $23.50

Canaccord Genuity raised its price target for CryoLife (NYSE:CRY) to $23.50 from $17.50 after the company reported third quarter results. The stock is changing hands at $17.10 on Thursday afternoon. Analyst Jason Mills...

NeoGenomics

BTIG upgrades NeoGenomics to buy

BTIG upgraded NeoGenomics (NASDAQ:NEO) to “buy” from “neutral,” with a price target of $10, after the company reported third quarter results. The stock closed at $7.13 on Wednesday. “When we downgraded shares at $9, our...

Fulgent Genetics

BTIG starts Fulgent Genetics at buy

BTIG initiated coverage of Fulgent Genetics (NASDAQ:FLGT) with a ‘buy” rating and $15 price target. The stock closed at $8.86 on Friday. “While the genetic testing market is not without challenges and competition is...

Tabula Rasa HealthCare

Stifel starts Tabula Rasa HealthCare at buy

Stifel launched coverage of Tabula Rasa HealthCare (NASDAQ:TRHC) with a “buy” rating and $17 price target. The stock closed at $14.23 on Friday. Tabula is a healthcare information technology company focused on...

Xenon Pharma

Stifel starts Xenon Pharma at buy

Stifel initiated coverage of Xenon Pharmaceuticals (NASDAQ:XENE) with a “buy” rating and $18 price target. The stock closed at $8.35 on Oct. 20. Analyst Stephen Willey writes that Xenon has successfully leveraged its...

AC Immune

Leerink starts AC Immune at outperform

Leerink initiated coverage of AC Immune SA (NASDAQ:ACIU) with an “outperform” rating and $22 price target. The stock closed at $14.43 on Friday. AC Immune is focused on developing novel medicines for neurodegenerative...

BioSyent

Cormark starts BioSyent at buy

Cormark Securities initiated coverage on BioSyent (TSX-V: RX) with a “buy” recommendation and $10.25 target price. The stock closed at $8.40 on Thursday. BioSyent establishes and builds out pharmaceutical brands in the...

Kura Oncology

Leerink resumes coverage of Kura at outperform

Leerink resumed coverage of Kura Oncology (NASDAQ:KURA) with an “outperform” rating and $15 price target. The stock closed at $5.60 on Wednesday. “We view Kura’s lead pipeline program, tipifarnib (a...

Alcobra Pharmaceuticals

Stifel downgrades Alcobra to hold

Stifel downgraded Alcobra (NASDAQ:ADHD) to “hold” from “buy” and slashed its price target to $3 from $17 after the FDA issued a clinical hold on the company’s Phase 3 study of metadoxine extended release (MDX) in adult...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.